2025
Bridging Radiotherapy Prior to Chimeric Antigen Receptor T-Cells for B-Cell Lymphomas: An ILROG Multicenter Study
Yegya-Raman N, Plastaras J, Wright C, Chelius M, Zhang S, Baron J, Hubbeling H, Sim A, Robinson T, Jain M, Imber B, Fregonese B, Yahalom J, Ladbury C, Dandapani S, Pinnix C, Gunther J, Fang P, Wu S, Dabaja B, Yang J, Chew J, Braunstein S, Sinha S, Delinger N, Sun S, Terezakis S, Sakthivel G, Constine L, Chowdhry A, Reagan P, Burke S, Tseng Y, LaRiviere M, Maity A, Schuster S, Chong E, Figura N. Bridging Radiotherapy Prior to Chimeric Antigen Receptor T-Cells for B-Cell Lymphomas: An ILROG Multicenter Study. Blood Advances 2025, 9: 3293-3303. PMID: 40203192, DOI: 10.1182/bloodadvances.2025015855.Peer-Reviewed Original ResearchConceptsChimeric antigen receptor T-cell therapyImmune effector cell-associated neurotoxicity syndromeSuperior progression-free survivalProgression-free survivalB-cell lymphomaCytokine release syndromeAssociated with superior progression-free survivalOverall survivalTwo-year progression-free survivalChimeric antigen receptor T cellsLactate dehydrogenaseRelapsed/refractory B-cell lymphomaLactate dehydrogenase normalizationAmerican Society for TransplantationT-cell therapyBaseline lactate dehydrogenaseMedian follow-upRetrospectively reviewed patientsAdvanced-stage diseaseHigh-risk cohortAxicabtagene ciloleucelBrexucabtagene autoleucelSystemic therapyMulticenter studyT cellsFunctional Correlates of Atypical Visuoperceptual Organization in a Multisite Clinical High-Risk Sample
Pokorny V, Tran T, Williams T, Kenney J, Silverstein S, Gold J, Waltz J, Schiffman J, Ellman L, Strauss G, Walker E, Woods S, Powers A, Corlett P, Mittal V. Functional Correlates of Atypical Visuoperceptual Organization in a Multisite Clinical High-Risk Sample. Journal Of Psychopathology And Clinical Science 2025, 134: 527-539. PMID: 40193439, PMCID: PMC12162206, DOI: 10.1037/abn0000992.Peer-Reviewed Original ResearchConceptsClinical high riskPsychotic-like Experiences groupClinical high-risk statusClinical high-risk samplesMeasures of cognitive abilityClinical high-risk groupHigh-risk sampleMeasuring perceptual organizationFaces taskPsychotic disordersPerceptual priorsCognitive abilitiesCognitive functionClinical groupsPerceptual organizationHealthy control groupContext-sensitiveSocial functioningTwo-tone imagesTarget circleSymbolic codeEbbinghausFunctional correlatesTaskParticipantsDebate 1: Radical Prostatectomy For the Right Patient With High-Risk Prostate Cancer
Sundaresan V, Leapman M. Debate 1: Radical Prostatectomy For the Right Patient With High-Risk Prostate Cancer. Seminars In Radiation Oncology 2025, 35: 385-392. PMID: 40516973, DOI: 10.1016/j.semradonc.2025.05.001.Peer-Reviewed Original ResearchConceptsAndrogen deprivation therapyRadical prostatectomyProstate cancerDeprivation therapyHigh riskEffect of long-term androgen-deprivation therapyLong-term androgen deprivation therapyAdequate randomized clinical trialsLong-term cancer controlHigh-risk prostate cancerRisk of gastrointestinal toxicityDisease-related survivalProportion of patientsDegrees of metastatic potentialResponse to treatmentRandomized clinical trialsCourse of treatmentSequence of surgeryLocal salvageRadiation therapySecondary malignanciesGastrointestinal toxicityInitial surgeryMultimodal treatmentHealth-related quality of lifeTiming of repeat epinephrine to inform paediatric anaphylaxis observation periods: a retrospective cohort study
Dribin T, Sampson H, Zhang Y, Boyd S, Zhang N, Michelson K, Neuman M, Brousseau D, Mistry R, Freedman S, Aronson P, Bergmann K, Boswell B, Chinta S, Chua W, Cohen A, Cohen J, Daggett A, Davis J, Freeman J, Khanna K, Knoles C, Kwan K, Larsen C, Lee J, Lubell T, Metcalf A, Moake M, Nesiama J, Ngo T, Pulcini C, Russo C, Singh N, Srivastava G, Strutt J, Thapar V, Vander Wyst C, Walsh P, Wolnerman Y, Schnadower D, Academy of Pediatrics P, Kanngiesser A, McGarghan F, Dulchavsky A, Costalez J, DesPain A, Armanious M, Haghnazarian E, Brown-Whitehorn T, Weigert R, Dayan P, Meltzer J, Chowdhury N, Benedetti J, Sinziana C, Handorf A, Ruthford M, Devens M, Mecham C, Holland J, Casas T, Brown J, Panda P, Morrow A, Maready M, Nathani Y, Stevens M, Abraham G, Yen K, Cooper-Sood J, Woolf S. Timing of repeat epinephrine to inform paediatric anaphylaxis observation periods: a retrospective cohort study. The Lancet Child & Adolescent Health 2025, 9: 484-496. PMID: 40506197, DOI: 10.1016/s2352-4642(25)00139-7.Peer-Reviewed Original ResearchConceptsElectronic medical recordsEmergency departmentRetrospective cohort studyCohort studyMedical recordsDocumentation of symptomsCardiovascular involvementHealth-care facilitiesEpinephrine doseAcute allergic reactionsNational Institutes of HealthCumulative incidenceNational Center for Advancing Translational SciencesInstitutes of HealthChildren aged 6 monthsClinical ModificationHospital wardsIncidence rateICD-10Observation periodPrimary outcomeAllergic reactionsSecondary to medicationsInitiation to discontinuationKaplan-Meier analysisThe Impact of Cognitive Impairment on Cardiovascular Disease
Jamil Y, Krishnaswami A, Orkaby A, Stimmel M, Brown Iv C, Mecca A, Forman D, Rich M, Nanna M, Damluji A. The Impact of Cognitive Impairment on Cardiovascular Disease. Journal Of The American College Of Cardiology 2025, 85: 2472-2491. PMID: 40562512, DOI: 10.1016/j.jacc.2025.04.057.Peer-Reviewed Original ResearchConceptsImpact of cognitive impairmentCognitive impairmentCardiovascular diseaseHealth care utilizationOlder adult populationEvidence-based management strategiesMedical adverse eventsHealth literacyCare utilizationOlder adultsMitigate cognitive impairmentUnder-prescribedReduced participationU.S. populationTreatment of patientsAdult populationGuideline-directedExcess morbidityCardiac patientsRisk factorsOlder patientsAdverse eventsHealthMechanism of cognitive impairmentInterventional managementCarcinogenic Industrial Air Emissions and Lung Cancer Risk in a Cohort of 440,000 Americans.
Madrigal J, Fisher J, Pruitt C, Liao L, Graubard B, Ward M, Silverman D, Jones R. Carcinogenic Industrial Air Emissions and Lung Cancer Risk in a Cohort of 440,000 Americans. American Journal Of Respiratory And Critical Care Medicine 2025, 211: 1241-1252. PMID: 40315142, DOI: 10.1164/rccm.202409-1738oc.Peer-Reviewed Original ResearchConceptsLung cancer riskCancer riskAssociated with riskNIH-AARP DietEvaluate lung cancer riskLung carcinogensAssociated with lung cancerCox proportional hazards modelsNIH-AARPHealth StudyProportional hazards modelSquamous cell carcinomaStrong associationsAssociated with benzeneHazards modelIndustrial air emissionsEnrollment residenceCell carcinomaOverall riskLung cancer developmentSmokingAssociationRiskHistological subtypesLung cancerComputational limitations and future needs to unravel the full potential of 2’-O-methylation and C/D box snoRNAs
Ramirez C, Perenthaler E, Lauria F, Tebaldi T, Viero G. Computational limitations and future needs to unravel the full potential of 2’-O-methylation and C/D box snoRNAs. RNA Biology 2025, 22: 1-11. PMID: 40377202, DOI: 10.1080/15476286.2025.2506712.Peer-Reviewed Original ResearchConsensus guideline for the management of gastric cancer with synchronous peritoneal metastases
Butensky S, Bansal V, Su D, Waheed M, Nikiforchin A, Gomez‐Mayorga J, Olecki E, Radomski S, Sun B, Turaga K, Gunderson C, Lacy J, Badgwell B, In H, Kennedy T, Yoon H, Greer J, Sundar R, Woo Y, Group P. Consensus guideline for the management of gastric cancer with synchronous peritoneal metastases. Cancer 2025, 131: e35870. PMID: 40558029, DOI: 10.1002/cncr.35870.Peer-Reviewed Original ResearchConceptsSynchronous peritoneal metastasesManagement of gastric cancerPeritoneal metastasisGastric cancerCytoreductive surgeryConsensus guidelinesLow peritoneal carcinomatosis indexPeritoneal carcinomatosis indexMultidisciplinary preoperative assessmentLimited treatment optionsPatient's goals of careLevel of evidenceGoals of careClinical management pathwaysCytology-negativeCytology-positiveRandomized controlled trialsDiagnostic laparoscopySystemic therapySurvival benefitBurden of diseasePreoperative assessmentNonsurgical managementDisease subsetsTreatment optionsIntratumoral IL12 mRNA administration activates innate and adaptive pathways in checkpoint inhibitor-resistant tumors resulting in complete responses
Lakshmipathi J, Santha S, Li M, Qian Y, Roy S, Luheshi N, Politi K, Bosenberg M, Eyles J, Muthusamy V. Intratumoral IL12 mRNA administration activates innate and adaptive pathways in checkpoint inhibitor-resistant tumors resulting in complete responses. Cancer Immunology, Immunotherapy 2025, 74: 250. PMID: 40560386, PMCID: PMC12198101, DOI: 10.1007/s00262-025-04105-0.Peer-Reviewed Original ResearchConceptsAnti-tumor immune responseTumor-associated macrophagesCytotoxic T cellsImmune responseActivity of checkpoint inhibitorsAnti-PD-L1 antibodyPhagocytosis of tumor cellsAnti-PD-L1Enhanced anti-tumorAntigen presentation machineryCell-based immune responsesMurine tumor modelsTh1-type cytokinesColorectal carcinoma tumorsICI resistanceMurine IL12Checkpoint inhibitorsPresentation machineryIntratumoral deliveryResistant tumorsAdvanced diseaseCarcinoma tumorsTumor microenvironmentMurine tumorsT cellsConsensus guideline for the management of patients with appendiceal tumors, part 1: Appendiceal tumors without peritoneal involvement
Godfrey E, Mahoney F, Bansal V, Su D, Hanna D, Lopez‐Ramirez F, Baron E, Turaga K, Benson A, Cusack J, Winer J, Gunderson C, Misdraji J, Shah R, Magge D, Solsky I, Eng C, Eng O, Shergill A, Shen J, Foote M, Group P. Consensus guideline for the management of patients with appendiceal tumors, part 1: Appendiceal tumors without peritoneal involvement. Cancer 2025, 131: e35867. PMID: 40558045, DOI: 10.1002/cncr.35867.Peer-Reviewed Original ResearchConceptsAppendiceal tumorsPeritoneal involvementConsensus guidelinesHeterogeneous group of tumorsSystemic therapy recommendationsGroup of tumorsManagement of patientsAppendiceal malignancyAppendiceal adenocarcinomaIntraperitoneal chemotherapyMucinous neoplasmsMargin statusModified Delphi consensusPathological findingsClinical dataColorectal cancerPathological classificationPathway blockTherapy recommendationsTumorConsensus recommendationsObservational studyTherapy conceptsHeterogeneous groupStandard careConsensus guideline for the management of patients with appendiceal tumors, part 2: Appendiceal tumors with peritoneal involvement
Godfrey E, Mahoney F, Bansal V, Su D, Hanna D, Lopez‐Ramirez F, Baron E, Turaga K, Benson A, Setia N, Winer J, Gunderson C, Shah R, Magge D, Solsky I, Eng C, Eng O, Shergill A, Shen J, Misdraji J, Foote M, Luo W, Group P. Consensus guideline for the management of patients with appendiceal tumors, part 2: Appendiceal tumors with peritoneal involvement. Cancer 2025, 131: e35874. PMID: 40558065, DOI: 10.1002/cncr.35874.Peer-Reviewed Original ResearchConceptsManagement of appendiceal tumoursAppendiceal tumorsPeritoneal involvementConsensus guidelinesTiming of systemic chemotherapyDelphi consensusHeterogeneous group of tumorsHigh-grade diseaseGroup of tumorsManagement of patientsModified Delphi consensusAppendiceal malignancySystemic chemotherapyUnresectable diseasePeritoneal diseaseSystemic therapySurgical candidatesMost patientsNon-neuroendocrineSurveillance protocolsStandard careColorectal cancerPathological classificationPathway blockConsensus recommendationsConsensus guideline for the management of peritoneal mesothelioma
Brown L, Wilkins S, Bansal V, Su D, Gomez‐Mayorga J, Turaga K, Gunderson C, Lee B, Nash G, Hays J, Raghav K, Husain A, Kluger M, Zauderer M, Kindler H, Alexander H, Group P. Consensus guideline for the management of peritoneal mesothelioma. Cancer 2025, 131: e35868. PMID: 40558081, DOI: 10.1002/cncr.35868.Peer-Reviewed Original ResearchConceptsPeritoneal mesotheliomaConsensus guidelinesManagement of peritoneal mesotheliomaTreatment of peritoneal mesotheliomaPathway blockAssessment of patient characteristicsHigh-risk patientsClinical trial enrollmentPresence of symptomsDisease histologyIntermediate-riskMultimodal therapyHigh quality evidenceMalignant pathologyClinicopathological featuresBenign neoplasmsSurgical interventionRare incidenceClinical evidencePatient characteristicsTrial enrollmentQuality evidenceMultidisciplinary assessmentTherapy timeMesotheliomaConsensus guideline for the management of peritoneal metastases from neuroendocrine neoplasms
Su D, Brown L, Bansal V, Bakkila B, Concors S, Turaga K, Gunderson C, Bergsland E, Strosberg J, Halfdanarson T, Metz D, Kunstman J, Kunz P, Gangi A, Group P. Consensus guideline for the management of peritoneal metastases from neuroendocrine neoplasms. Cancer 2025, 131: e35871. PMID: 40558053, DOI: 10.1002/cncr.35871.Peer-Reviewed Original ResearchConceptsManagement of neuroendocrine neoplasmsPeritoneal metastasisNeuroendocrine neoplasmsConsensus guidelinesManagement of peritoneal metastasesClinical management of patientsManagement of PMManagement of patientsComplex clinical challengeLevel of evidenceCytoreductive surgerySurgical resectionSystemic therapyClinical managementClinical challengeLow incidenceModified Delphi techniquePathway blockDisease gradeGrade 1Therapy conceptsHeterogeneous phenotypesFunctional syndromesMultidisciplinary approachMetastasisPsychological Interventions for Reducing Distress in Patients with Cardiac Arrhythmias
Särnholm J, Gaffey A, Turchio M, Biviano A, Burg M. Psychological Interventions for Reducing Distress in Patients with Cardiac Arrhythmias. Current Cardiology Reports 2025, 27: 102. PMID: 40560300, PMCID: PMC12198271, DOI: 10.1007/s11886-025-02253-4.Peer-Reviewed Original ResearchConceptsCognitive behavioral therapyPsychological healthPsychological interventionsAssociated with anxietyBehavioral therapyAvoidance behaviorReduce distressArrhythmia careReduce anxietyPoor quality of lifeAnxietyDepressionQuality of lifeCare CollaborativeCare systemImprove QoLInterventionCareSummaryFurther researchHealthPoor qualityDistressQoLAvoidanceFearPediatric Nonfatal Firearm Injury Health Care Utilization.
Du J, Andrews A, Gastineau K, Lee L, Ranney M, Sacks C, Song Z, Fleegler E, Pulcini C. Pediatric Nonfatal Firearm Injury Health Care Utilization. 2025, 156 PMID: 40555422, DOI: 10.1542/peds.2024-070424.Peer-Reviewed Original ResearchConceptsFirearm injuriesHealth care outcomesHealth care useHealth care utilizationMental health diagnosesPediatric firearm injuriesHealth care spendingCare outcomesCare useInjury preventionCare utilizationPostinjury careInjured childrenHealth diagnosisCare spendingPrevention effortsHealth impactsIntervention effortsHealthLongitudinal researchChildrenPostinjuryCost-effectiveFirearmUnited StatesDynamic interaction of spliceosomal snRNPs with coilin explains Cajal body characteristics
Basello D, Blažíková M, Roithová A, Hálová M, Radivojević N, Neugebauer K, Staněk D. Dynamic interaction of spliceosomal snRNPs with coilin explains Cajal body characteristics. Journal Of Cell Biology 2025, 224: e202309128. PMID: 40560171, PMCID: PMC12189012, DOI: 10.1083/jcb.202309128.Peer-Reviewed Original ResearchConsensus guideline for the management of colorectal cancer with peritoneal metastases
Schultz K, Bansal V, Wach M, Bhutiani N, Godley F, Wang J, Waheed M, Buchheit J, Papai E, Campbell S, Schleimer L, Su D, Turaga K, Gunderson C, White M, Uppal A, Raghav K, Labow D, Sarpel U, Shergill A, Shen J, Eng C, Foote M, Baumgartner J, Group P. Consensus guideline for the management of colorectal cancer with peritoneal metastases. Cancer 2025, 131: e35869. PMID: 40558054, DOI: 10.1002/cncr.35869.Peer-Reviewed Original ResearchConceptsManagement of colorectal cancerCRC-PMColorectal cancerPeritoneal metastasisConsensus guidelinesPeritoneal surface malignancy centersCirculating tumor DNA testingUpfront cytoreductive surgerySite of metastasisProspective multicenter trialOptimal treatment strategyAssess agreement levelsLevel of evidenceOverall level of evidenceClinical management pathwaysModified Delphi techniqueCytoreductive surgerySystemic therapyMulticenter trialRisk stratificationTreatment strategiesPathway blockWeak recommendationPathological featuresMetastasisThe Impact and Safety of GLP‐1 Agents and Breast Cancer
Parsons K, Montalvo M, Fischbach N, Taylor M, Alfaro S, Lustberg M. The Impact and Safety of GLP‐1 Agents and Breast Cancer. Cancer Medicine 2025, 14: e70932. PMID: 40552446, PMCID: PMC12186097, DOI: 10.1002/cam4.70932.Peer-Reviewed Original ResearchConceptsBreast cancer patientsGLP-1 receptor agonistsBreast cancerBreast cancer-specific mortalityCancer patientsBreast cancer incidenceBreast cancer ratesWeight management interventionsProportion of breast cancer patientsNon-cancer populationObese post-menopausal womenReceptor agonistsBreast cancer outcomesBreast cancer progressionWeight loss interventionWeight management strategiesEffective weight managementGLP-1Quality of lifeAll-cause mortalityCancer-specific mortalityImprove patient outcomesObesity prevalenceWeb of ScienceCancer incidenceA Vaccine to Block Plasmodium falciparum Transmission.
Healy S, Sagara I, Assadou M, Katile A, Kone M, Imeru A, Kwan J, Swihart B, Fintzi J, Potter G, Zeguimé A, Dolo A, Diarra B, Narum D, Rausch K, MacDonald N, Zhu D, Mohan R, Thera I, Morrison R, Zaidi I, Doritchamou J, Sylla D, Hume J, Coulibaly M, Morelle D, Lievens M, Doumbo O, Duffy P. A Vaccine to Block Plasmodium falciparum Transmission. NEJM Evidence 2025, 4: evidoa2400188. PMID: 40552966, DOI: 10.1056/evidoa2400188.Peer-Reviewed Original ResearchConceptsStandard membrane feeding assayPfs230D1-EPASafety trialsAntibody responseEnd pointsSkin feeding assaysTransmission-reducing activityWeeks of follow-upMembrane feeding assaysAs-treated populationPrimary efficacy analysisSecondary end pointsPrimary end pointInfected mosquitoesEnzyme-linked immunosorbent assayMalian adultsMalaria vaccineComparator-controlledDouble-blindProportion of infected mosquitoesDosing regimensEfficacy analysisThird doseYears postvaccinationBlock disease transmissionSulopenem versus Amoxicillin/Clavulanate for the Treatment of Uncomplicated Urinary Tract Infection.
Puttagunta S, Aronin S, Gupta J, Das A, Gupta K, Dunne M. Sulopenem versus Amoxicillin/Clavulanate for the Treatment of Uncomplicated Urinary Tract Infection. NEJM Evidence 2025, 4: evidoa2400414. PMID: 40552968, DOI: 10.1056/evidoa2400414.Peer-Reviewed Original ResearchConceptsUrinary tract infectionUncomplicated urinary tract infectionsIntent-to-treat populationSusceptible to amoxicillin/clavulanateTract infectionsUrine cultureAdverse eventsTreatment of uncomplicated urinary tract infectionsCombined population of patientsPatients treated with amoxicillin/clavulanateTreatment-emergent adverse eventsBaseline urine culturePositive urine cultureMild adverse eventsPopulation of patientsTreatment of adult womenClasses of antibioticsMicrobiological eradicationBaseline pathogensClinical cureDouble-blindMedian ageTrial medicationAmoxicillin/clavulanateAntimicrobial resistance
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply